Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Phathom Pharmaceuticals (PHAT) Net Income towards Common Stockholders (2022 - 2025)

Historic Net Income towards Common Stockholders for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Q3 2025 value amounting to -$30.0 million.

  • Phathom Pharmaceuticals' Net Income towards Common Stockholders rose 6498.03% to -$30.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$274.4 million, marking a year-over-year increase of 1914.08%. This contributed to the annual value of -$334.3 million for FY2024, which is 6599.37% down from last year.
  • As of Q3 2025, Phathom Pharmaceuticals' Net Income towards Common Stockholders stood at -$30.0 million, which was up 6498.03% from -$75.7 million recorded in Q2 2025.
  • In the past 5 years, Phathom Pharmaceuticals' Net Income towards Common Stockholders ranged from a high of -$30.0 million in Q3 2025 and a low of -$94.3 million during Q1 2025
  • Over the past 4 years, Phathom Pharmaceuticals' median Net Income towards Common Stockholders value was -$55.0 million (recorded in 2022), while the average stood at -$62.2 million.
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first tumbled by 12319.86% in 2024, then skyrocketed by 6498.03% in 2025.
  • Quarter analysis of 4 years shows Phathom Pharmaceuticals' Net Income towards Common Stockholders stood at -$55.0 million in 2022, then plummeted by 44.76% to -$79.6 million in 2023, then rose by 6.36% to -$74.5 million in 2024, then skyrocketed by 59.78% to -$30.0 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$30.0 million for Q3 2025, versus -$75.7 million for Q2 2025 and -$94.3 million for Q1 2025.